Dynamics and kinetics of ophthalmic timolol
- PMID: 7357805
- DOI: 10.1038/clpt.1980.66
Dynamics and kinetics of ophthalmic timolol
Abstract
Timolol is a beta adrenergic antagonist in 0.25% or 0.5% eyedrop solution for glaucoma. In a double-blind crossover study in healthy males we measured systemic beta blockade, intraocular pressure, and timolol kinetics after the first and ninth 12-hourly dose of a 0.5% ophthalmic solution. Timolol ophthalmic and placebo were each given as 2 drops to each eye with precautions to prevent the normal loss of drug in tears and overflow (high dose) and as 1 drop to each eye with no special precautions (standard therapeutic dose). Exercise tachycardia, measured at 70 and 255 min after administration of drug, was lower at both levels. Postexercise 1-sec forced expiratory volume (FEV1) was not affected. Intraocular pressure measured at 3 and 8 hr after drug was lower at both dose levels. Timolol was consistently present in urine but was not detectable in most plasma samples. Dynamic effects were not greater after the ninth than after the first dose, and the urinary excretion data provided no evidence of drug cumulation.
Similar articles
-
Effect of ophthalmic administration of S-596 (Arotinolol) on intraocular pressure and haemodynamics in health volunteers: comparison with timolol.Eur J Clin Pharmacol. 1985;28(4):391-6. doi: 10.1007/BF00544356. Eur J Clin Pharmacol. 1985. PMID: 2411566 Clinical Trial.
-
Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers.J Clin Pharmacol. 2000 Feb;40(2):193-9. doi: 10.1177/00912700022008739. J Clin Pharmacol. 2000. PMID: 10664926 Clinical Trial.
-
Assessment of bronchial effects following topical administration of butylamino-phenoxy-propanol-acetate, an oculoselective beta-adrenoceptor blocker in asthmatic subjects.Br J Clin Pharmacol. 1992 Aug;34(2):122-9. doi: 10.1111/j.1365-2125.1992.tb04120.x. Br J Clin Pharmacol. 1992. PMID: 1358158 Free PMC article. Clinical Trial.
-
Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma.Drugs. 1979 Jan;17(1):38-55. doi: 10.2165/00003495-197917010-00002. Drugs. 1979. PMID: 369807 Review.
-
Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects.Scand J Clin Lab Invest. 2007;67(2):237-45. doi: 10.1080/00365510601034736. Scand J Clin Lab Invest. 2007. PMID: 17366003 Review.
Cited by
-
Topical timolol and serum lipoproteins.Br J Ophthalmol. 1990 Nov;74(11):663-4. doi: 10.1136/bjo.74.11.663. Br J Ophthalmol. 1990. PMID: 2223703 Free PMC article. Clinical Trial.
-
Ophthalmic Timolol and Hospitalization for Symptomatic Bradycardia and Syncope: A Case Series.Cureus. 2020 Mar 14;12(3):e7270. doi: 10.7759/cureus.7270. Cureus. 2020. PMID: 32292680 Free PMC article.
-
Effect of ophthalmic administration of S-596 (Arotinolol) on intraocular pressure and haemodynamics in health volunteers: comparison with timolol.Eur J Clin Pharmacol. 1985;28(4):391-6. doi: 10.1007/BF00544356. Eur J Clin Pharmacol. 1985. PMID: 2411566 Clinical Trial.
-
Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol.Clin Med Res. 2019 Dec;17(3-4):90-96. doi: 10.3121/cmr.2019.1486. Epub 2019 Aug 28. Clin Med Res. 2019. PMID: 31462538 Free PMC article. Review.
-
Association between Ophthalmic Timolol and Hospitalisation for Bradycardia.J Ophthalmol. 2015;2015:567387. doi: 10.1155/2015/567387. Epub 2015 Mar 22. J Ophthalmol. 2015. PMID: 25874117 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources